4DMedical Ltd (ASX: 4DX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
4DMedical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$195.33 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
410.53 million
Earnings per share
-0.087
Dividend per share
N/A
Year To Date Return
-41.96%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
4DMedical Ltd (ASX: 4DX)
Latest News
Share Gainers
Why is the 4DMedical (ASX:4DX) share price rocketing 30% today?
Healthcare Shares
4DMedical (ASX:4DX) share price launches 19% on first commercial scans
Healthcare Shares
4DMedical (ASX:4DX) share price gains amid boss' confidence for FY22
Share Market News
ASX 200 falls, Metcash down, 4DMedical drops
Healthcare Shares
4DMedical (ASX:4DX) share price is lifting on its COVID-related technology
Earnings Results
4DMedical (ASX:4DX) share price lifts on 71% income increase in FY21
Share Gainers
4DMedical (ASX:4DX) share price soars on contract with $305b pharma giant
Healthcare Shares
Here's why the 4DMedical (ASX:4DX) share price is gaining today
Healthcare Shares
4DMedical (ASX:4DX) share price flies 5% higher on purchase order
Share Market News
The Island Pharma (ASX:ILA) share price lifts on key US patent milestone
Healthcare Shares
The 4DMedical (ASX:4DX) share price is down 38% in 2021
Healthcare Shares
4DMedical (ASX:4DX) share price wobbles on quarterly report
Frequently Asked Questions
-
No, 4DMedical does not pay dividends at this time.
-
4DMedical listed on the ASX on 7 August 2020.
4DX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About 4DMedical Ltd
4DMedical Ltd (ASX: 4DX) is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.
The company's non-invasive lung imaging technology emanates from research work undertaken at Monash University. It is the first FDA-cleared respiratory imaging solution that uses mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data.
The technology uses existing imaging systems and allows X-ray images to be taken simultaneously from various angles. Using image-processing methods adapted from aerospace engineering, the motion of lung tissue can be measured. This allows ventilation to be calculated at each stage of the breath and at every location within the lung. These measurements are then visualized as a coloured heat map to help medical professionals accurately identify ventilation deficits.
The 4DMedical technology is patented in key jurisdictions, including the US and Australia. The company is aiming to secure a slice of the global lung imaging market. The US market alone was valued at more than $US30 billion in normal pre-COVID diagnostic conditions.
4DX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Nov 2024 | $0.48 | $-0.04 | -7.84% | 667,517 | $0.52 | $0.52 | $0.48 |
| 19 Nov 2024 | $0.51 | $0.03 | 6.25% | 1,600,347 | $0.54 | $0.54 | $0.49 |
| 18 Nov 2024 | $0.48 | $-0.01 | -2.06% | 433,791 | $0.48 | $0.49 | $0.47 |
| 15 Nov 2024 | $0.49 | $0.01 | 2.08% | 509,706 | $0.48 | $0.49 | $0.47 |
| 14 Nov 2024 | $0.48 | $-0.02 | -4.04% | 581,864 | $0.49 | $0.49 | $0.47 |
| 13 Nov 2024 | $0.50 | $0.02 | 4.17% | 274,863 | $0.49 | $0.50 | $0.48 |
| 12 Nov 2024 | $0.48 | $-0.02 | -4.00% | 1,036,137 | $0.51 | $0.51 | $0.48 |
| 11 Nov 2024 | $0.50 | $-0.02 | -3.85% | 409,938 | $0.52 | $0.52 | $0.50 |
| 08 Nov 2024 | $0.52 | $-0.01 | -1.90% | 337,155 | $0.52 | $0.54 | $0.51 |
| 07 Nov 2024 | $0.53 | $0.01 | 1.94% | 96,923 | $0.53 | $0.53 | $0.52 |
| 06 Nov 2024 | $0.52 | $-0.01 | -1.90% | 239,263 | $0.53 | $0.54 | $0.52 |
| 05 Nov 2024 | $0.53 | $-0.02 | -3.70% | 246,110 | $0.54 | $0.54 | $0.53 |
| 04 Nov 2024 | $0.54 | $0.01 | 1.87% | 364,927 | $0.54 | $0.55 | $0.53 |
| 01 Nov 2024 | $0.54 | $0.01 | 1.89% | 165,414 | $0.53 | $0.54 | $0.52 |
| 31 Oct 2024 | $0.53 | $0.02 | 3.92% | 550,527 | $0.53 | $0.53 | $0.51 |
| 30 Oct 2024 | $0.51 | $0.01 | 1.98% | 137,689 | $0.51 | $0.53 | $0.51 |
| 29 Oct 2024 | $0.51 | $-0.01 | -1.94% | 389,771 | $0.51 | $0.53 | $0.50 |
| 28 Oct 2024 | $0.52 | $0.01 | 1.96% | 288,583 | $0.51 | $0.52 | $0.50 |
| 25 Oct 2024 | $0.51 | $0.00 | 0.00% | 750,076 | $0.53 | $0.53 | $0.50 |
| 24 Oct 2024 | $0.51 | $-0.01 | -1.92% | 491,207 | $0.52 | $0.53 | $0.51 |
| 23 Oct 2024 | $0.52 | $0.01 | 1.94% | 581,253 | $0.57 | $0.58 | $0.52 |
| 22 Oct 2024 | $0.52 | $-0.01 | -1.92% | 222,769 | $0.53 | $0.53 | $0.51 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 07 Aug 2024 | Andreas Fouras | Expiry | 914,000 | $411,300 |
Options expired.
|
| 04 Mar 2024 | Lilian (Lil) Bianchi | Exercise | 40,000 | $29,000 |
Exercise of options.
|
| 04 Mar 2024 | Lilian (Lil) Bianchi | Buy | 40,000 | $29,000 |
Exercise of options.
|
| 04 Mar 2024 | Geraldine McGinty | Buy | 40,000 | $29,000 |
Exercise of options.
|
| 04 Mar 2024 | Geraldine McGinty | Exercise | 40,000 | $29,000 |
Exercise of options.
|
| 23 Jan 2024 | Lilian (Lil) Bianchi | Issued | 40,000 | $31,600 |
Director remuneration.
|
| 23 Jan 2024 | Geraldine McGinty | Issued | 40,000 | $31,600 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr John Andrew Livingston | Executive Director | Mar 2018 |
Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where John was Chief Executive Officer and Managing Director.
|
| Dr Robert Alan Figlin | Non-Executive Director | Dec 2016 |
Dr Figlin held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Robert serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, The Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He is Chair of the Medical Advisory Committee.
|
| Dr Andreas Fouras | Chief Executive OfficerManaging Director | Dec 2012 |
Dr Fouras career in academic research has a foundation gained within studying experimental fluid dynamics in the Department of Mechanical and Aerospace Engineering at Monash University in Melbourne, Australia. This research into wind tunnel quantification garnered recognition as a young leader in the scientific discipline of fluid dynamics, developing a number of new approaches to the imaging of gas and liquid flow. He is member of the Medical Advisory Committee.
|
| Ms Lilian (Lil) Bianchi | Non-Executive DirectorNon-Executive Chairman | Dec 2019 |
Ms Bianchi is an experienced Non-Executive Director with a focus on innovative companies operating in highly regulated environments including health, finance and infrastructure. She is Chair of the Risk Committee.
|
| Mr Julian Bernard Kingsley Sutton | Non-Executive Director | Sep 2017 |
Mr Sutton began his career as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. He later worked for Towers Perrin in Brussels and London as an asset consultant before moving to Credit Suisse Asset Management and then Schroders Investment Management as a portfolio manager in their respective multi-manager teams. He is member of Risk Committee.
|
| Dr Geraldine Bernadette McGinty | Non-Executive Director | Sep 2023 |
Dr McGinty is an expert in health care strategy and imaging economics, and prominent advocate for patient-centred care. A Professor of Clinical Radiology and Population Health Sciences at Weill Cornell Medicine in New York City, she serves as Senior Associate Dean for Clinical Affairs. He is member of the Medical Advisory Committee.
|
| Ms Naomi Lawrie | Company SecretaryGeneral Counsel | Apr 2023 |
-
|
| Matt Tucker | Chief Commercial Officer |
-
|
|
| Simon Glover | Chief Financial Officer |
-
|
|
| Naomi Lawrie | Company SecretaryGeneral Counsel |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Velocimetry Consulting Pty Ltd | 64,838,000 | 15.79% |
| Citicorp Nominees Pty Limited | 23,268,218 | 5.67% |
| BNP Paribas Nominees Pty Ltd | 19,897,389 | 4.85% |
| HSBC Custody Nominees (Australia) Limited | 14,435,511 | 3.52% |
| Ryder Innovation Fund LP | 4,551,274 | 1.11% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,179,399 | 1.02% |
| Merrill Lynch (Australia) Nominees Pty Limited | 3,573,454 | 0.87% |
| Mr Damen Diamantopoulos | 3,090,000 | 0.75% |
| JP Morgan Nominees Australia Pty Limited | 2,806,425 | 0.68% |
| Alex Petrou & Christine Petrou | 2,484,471 | 0.61% |
| Mr Paul Tomlin | 2,416,870 | 0.59% |
| BNP Paribas Noms Pty Ltd | 2,101,511 | 0.51% |
| Pacific Custodians Pty Limited | 2,040,978 | 0.50% |
| Mrs Irene Wai-Ping Lee & Miss Yvonne Lee & Mr Wilson Lee | 1,997,346 | 0.49% |
| Sprout Group Pty Ltd | 1,769,331 | 0.43% |
| BNP Paribas Nominees Pty Ltd i | 1,737,816 | 0.42% |
| Mr Dev Jayram | 1,580,583 | 0.39% |
| Fang Family Investments Pty Ltd | 1,517,437 | 0.37% |
| Endless Smiles Pty Ltd | 1,500,000 | 0.37% |
| Wal Assets Pty Ltd | 1,411,487 | 0.34% |
